Literature DB >> 15073752

Geographical variation in adverse event reporting rates in clinical trials.

S Joelson1, I B Joelson, M A Wallander.   

Abstract

A group of 13,698 patients from 127 gastro-intestinal clinical trials, conducted in 13 countries was included in the analyses. All adverse events reported were included in the evaluation. The general adverse event reporting rate, the mean number of adverse events reported, the serious adverse event reporting rate and the mean number of serious adverse events reported were calculated for each country. In addition, the pattern of adverse events reported in each country was studied. The general adverse event reporting rate varied between 17% and 68% with a mean of 47% and the serious adverse event reporting rate varied between 1% and 20% with a mean of 8%. The mean number of adverse events, reported by patients reporting adverse events, varied between 1.5 and 2.7 with a mean of 2.1 and the mean number of serious adverse events, reported by patients reporting serious adverse events, varied between 1.1 and 1.7 with a mean of 1.4. In addition to these differences, patients/investigators had a tendency to put emphasis on different kinds of adverse events in different countries. Copyright 1997 John Wiley & Sons, Ltd.

Entities:  

Year:  1997        PMID: 15073752     DOI: 10.1002/(sici)1099-1557(199710)6:3+<s31::aid-pds288>3.3.co;2-w

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  8 in total

1.  Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.

Authors:  Glen R B Irving; Lynne M Howells; Stewart Sale; Ines Kralj-Hans; Wendy S Atkin; Susan K Clark; Robert G Britton; Donald J L Jones; Edwina N Scott; David P Berry; David Hemingway; Andrew S Miller; Karen Brown; Andreas J Gescher; William P Steward
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-11

2.  Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.

Authors:  Ying-Lu Guo; Vijay P Viswanathan; Han-Sun Chiang; Hyung Ki Choi; Andrew Wai Chun Yip; Wei Shen; Vladimir Kopernicky
Journal:  Asian J Androl       Date:  2009-04-20       Impact factor: 3.285

3.  Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.

Authors:  Karen Cheng; Paul Newell; Joseph W Chow; Helen Broadhurst; David Wilson; Katrina Yates; Angela Wardman
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.606

4.  Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59® -adjuvanted influenza vaccine in older adults: Results from three consecutive seasons.

Authors:  Donatella Panatto; Mendel Haag; Piero Luigi Lai; Sylvie Tomczyk; Daniela Amicizia; Maria Maddalena Lino
Journal:  Influenza Other Respir Viruses       Date:  2019-10-16       Impact factor: 4.380

5.  Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?

Authors:  David H Canaday; Stefan Gravenstein; Oladayo A Oyebanji; Brigid Wilson; Debbie Keresztesy; Lenore Carias; Dennis Wilk; Michael Payne; Htin Aung; Kerri St Denis; Evan C Lam; Christopher F Rowley; Sarah D Berry; Cheryl M Cameron; Mark J Cameron; Kenneth E Schmader; Alejandro B Balazs; Christopher L King
Journal:  Aging Clin Exp Res       Date:  2021-10-15       Impact factor: 3.636

6.  Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.

Authors:  M E J Lean; R Carraro; N Finer; H Hartvig; M L Lindegaard; S Rössner; L Van Gaal; A Astrup
Journal:  Int J Obes (Lond)       Date:  2013-08-14       Impact factor: 5.095

7.  Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting.

Authors:  Gwenllian Moody; Katy Addison; Rebecca Cannings-John; Julia Sanders; Carolyn Wallace; Michael Robling
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

8.  Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials.

Authors:  Daniel Keebler; Edmond Teng; Jenny Chia; Joshua Galanter; Jodie Peake; Katie Tuckwell
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.